^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    KIT (KIT proto-oncogene, receptor tyrosine kinase)

    i
    Other names: KIT, KIT proto-oncogene receptor tyrosine kinase, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
    3d
    Clinicopathological and molecular genetic analysis of 13 cases of primary retroperitoneal Ewing sarcoma. (PubMed, Ann Diagn Pathol)
    RES is an aggressive, high-grade tumor, prone to multiple recurrences and metastases, with distinctive morphologic, immunohistochemical, and molecular genetic features. ERCC4 splicing mutation, which is a novel pathogenic variant discovered for the first time, with possible significance for understanding the disease, as well as the development of targeted drugs.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • EWSR1 (EWS RNA Binding Protein 1) • NCAM1 (Neural cell adhesion molecule 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • CD99 (CD99 Molecule) • PAX7 (Paired Box 7)
    |
    ERCC4 mutation
    3d
    DNA-based FeCuAg nanoclusters with peroxidase-like and GSH depletion activities for toxicity of in vitro cancer cells. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc)
    More importantly, c-kit-TBA-FeCuAg NCs were able to deplete largely the intracellular GSH and thus generate lots of endogenous ROS in HeLa cells, thereby exhibiting the significant and specific in vitro cancer cells toxicity. Therefore, c-kit-TBA-FeCuAg NCs, with peroxidase-like activity and glutathione (GSH) consumption ability, hold the ROS-based promising therapeutic effects for cancer.
    Preclinical • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    6d
    Clinical Characteristics and Diagnosis of Ph-Positive Mixed Phenotype Acute Leukemia. (PubMed, Clin Lab)
    Mixed phenotype acute leukemia (MPAL) is a rare type of malignant hematologic disease. Its diagnosis is based on the comprehensive evaluation of bone marrow cell morphology, immunophenotype, molecular and cytogenetic features.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CD9 (CD9 Molecule) • MME (Membrane Metalloendopeptidase) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • ANPEP (Alanyl Aminopeptidase, Membrane) • MPO (Myeloperoxidase)
    |
    CD38 expression • CD19 expression • CD123 expression • IL3RA expression
    6d
    The carcinogenic capacity of arsenic in normal epithelial breast cells and double-positive breast cancer cells. (PubMed, Med Pharm Rep)
    In our current research, we aimed to simulate the effects of chronic low-level arsenic exposure on breast cells by intoxicating MCF-10A and MCF-7 cells with 1 μM Arsenic trioxide (As2O3) for 3 weeks (3w) and 6 weeks (6w), respectively...Furthermore, MCF-7 cells exhibited unique mutations in the KIT Proto-Oncogene (KIT) (c.1594G>A) and TP53 (c.215C>G). In summary, our study reveals that a 6-weeks exposure to arsenic has a limited carcinogenic effect in normal breast cells and a dual role in breast cancer cells.
    Journal • Tumor mutational burden
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • KDR (Kinase insert domain receptor) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • CSF1R (Colony stimulating factor 1 receptor) • SMARCD3 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 3)
    |
    TP53 mutation • HER-2 mutation • KIT mutation
    |
    arsenic trioxide
    10d
    Long-term combination therapy with metformin and oxymetholone in a Fanconi anemia mouse model. (PubMed, Pediatr Blood Cancer)
    Hematopoietic stem cell quiescence in mutant mice was enhanced by treatment with metformin alone. Metformin treatment caused a partial normalization of gene expression in the livers of mutant mice.
    Preclinical • Journal • Combination therapy
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • FANCD2 (FA Complementation Group D2)
    |
    metformin
    10d
    Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. (PubMed, Cancers (Basel))
    Compared to KIT/PDGFRA-mutant GIST, limited benefit was observed with imatinib in triple-negative GIST. In depth molecular profiling can be helpful in identifying driver mutations and guiding therapy.
    Journal • Next-generation sequencing • Stroma
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • ETV6 (ETS Variant Transcription Factor 6) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • AURKA (Aurora kinase A) • SDHC (Succinate Dehydrogenase Complex Subunit C) • SDHD (Succinate Dehydrogenase Complex Subunit D) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • NTRK3 fusion • PTEN deletion • PTEN mutation • NF1 mutation • ETV6-NTRK3 fusion • CHEK2 mutation • PDGFRA mutation • FANCA mutation • FGFR1 fusion • FANCA deletion • PDGFR wild-type
    |
    imatinib
    10d
    Quercetin promotes the proportion and maturation of NK cells by binding to MYH9 and improves cognitive functions in aged mice. (PubMed, Immun Ageing)
    In summary, our findings suggest that quercetin promotes the proportion and maturation of NK cells by binding to the MYH9 protein, thereby improving cognitive performance in middle-aged mice.
    Preclinical • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • MYH9 (Myosin Heavy Chain 9)
    11d
    Leiomyosarcoma of the esophagus, arising from lamina muscularis mucosae, in a combination with microinvasive squamous cell carcinoma-A case report. (PubMed, Indian J Pathol Microbiol)
    Microinvasive well-differentiated squamous cell carcinoma was also noted in the mucosa at the borders between the tumor and the healthy part of the esophagus. The aim of the manuscript is to present an extremely rare case of combined polypoid leiomyosarcoma and microinvasive squamous cell carcinoma of the esophagus, cured by robot-assisted surgical intervention and to emphasize that such cases should be examined carefully, including additional diagnostic tests such as Immunohistochemistry (IHC) in order to define the correct diagnosis.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • TP63 (Tumor protein 63)
    12d
    A new Finnish flavor of feline coat coloration, "salmiak," is associated with a 95-kb deletion downstream of the KIT gene. (PubMed, Anim Genet)
    Additional PCR genotyping of 180 domestic cats and three salmiak-colored cats confirmed the homozygous derived variant genotype fully concordant with the salmiak phenotype. We suggest the newly identified variant be designated as wsal for "w salmiak".
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    16d
    Improvement of functional dyspepsia with Suaeda salsa (L.) Pall via regulating brain-gut peptide and gut microbiota structure. (PubMed, Eur J Nutr)
    S. salsa has a certain therapeutic effect on mice with the syndrome of indigestion. From the perspective of "brain-gut-gut microbiota", the mechanism of digestion and accumulation of S. salsa was discussed for the first time, which provided an experimental basis for further exploring the material basis of S. salsa.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    17d
    Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation. (PubMed, Br J Haematol)
    Classically, cytogenetic aberrations are not common except in cases of SM associated with another haematological neoplasm. We highlight here an unusual clinical presentation of SM and demonstrate the utility of advanced cytogenetic analysis (optical genome mapping, OGM) in detecting a novel cytogenetic abnormality resulting in an unusual mechanism of DNMT3A and TET2 loss of function.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2)
    |
    KIT mutation • KIT D816V • TET2 deletion
    20d
    Additional prognostic value of polymorphisms within the 3'-untranslated region of programmed cell death pathway genes in early-stage breast cancer. (PubMed, Front Immunol)
    Receiver operating characteristic curve analysis demonstrated that incorporating unfavorable genotypes and clinicopathological variables improved the ability to predict EBC survival (P = 0.006, 0.004, 0.029, and 0.019 for iDFS, DDFS, BCSS, and OS, respectively). Additionally, rs6753785 and rs2213181 were associated with BCL2L11 and c-Kit mRNA expression, respectively. Our results suggest that these four SNPs may act as novel biomarkers for EBC survival, possibly by modulating the expression of the corresponding genes.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2L11 (BCL2 Like 11) • ATG2B (Autophagy Related 2B)
    |
    KIT expression
    21d
    Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review. (PubMed, Otolaryngol Head Neck Surg)
    ICI therapy can be an effective in select SNMM patients, especially those with advanced/metastatic disease.
    Review • Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    BRAF mutation • NRAS mutation • KIT mutation
    22d
    Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software. (PubMed, J Vis Exp)
    Mast cells displayed the greatest AF in all regions of interest (ROIs). Mast cells in the peritumor region and IM showed a positive prognostic significance.
    Retrospective data • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    23d
    Immunohistochemical marker profiles for the differentiation of collagenous spherulosis from adenoid cystic carcinoma of the breast. (PubMed, Hum Pathol)
    In summary, IHC for GATA3 and E-cadherin may contribute to the differential diagnosis between CS and ACC, although these markers are not exclusively expressed in either lesion. Histologic evaluation has to take into account that CS is frequently colonized by LCIS, requiring thorough correlation of histomorphology and immunohistochemical features.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CDH1 (Cadherin 1) • MME (Membrane Metalloendopeptidase) • TP63 (Tumor protein 63) • CDH3 (Cadherin 3) • GATA3 (GATA binding protein 3)
    |
    CDH1 expression
    25d
    FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. (PubMed, Curr Issues Mol Biol)
    The FLT3 and IRAK4 inhibitor emavusertib (CA4948), the MCL1 inhibitor S63845, the BCL2 inhibitor venetoclax, and the HSP90 inhibitor PU-H71 were assessed as single agents and in combination for their ability to induce apoptosis and cell death in leukemic cells in vitro. The combination of CA4948 and BH3-mimetics may be effective in the treatment in FLT3-mutated AML with differential target specificity for MCL1 and BCL2 inhibitors. Moreover, the combination of CA4948 and PU-H71 may be a candidate combination treatment in FLT3-mutated AML.
    Journal • Combination therapy • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • CD34 (CD34 molecule) • ITGAM (Integrin, alpha M) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
    |
    FLT3-ITD mutation • FLT3 mutation • NPM1 mutation
    |
    Venclexta (venetoclax) • S63845 • emavusertib (CA-4948) • zelavespib intravenous (PU-H71 IV)
    25d
    Flow cytometric immunophenotypic differentiation patterns of bone marrow eosinophilopoiesis. (PubMed, Cytometry B Clin Cytom)
    A novel flow cytometric antibody panel was devised to detect alterations in immunophenotypic patterns of bone marrow eosinophil maturation and evaluated in normal, HES and SM samples. This approach will allow us to elucidate changes in immunophenotypic patterns of bone marrow eosinophilopoiesis in other hematological diseases.
    Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule) • ICAM1 (Intercellular adhesion molecule 1) • CD9 (CD9 Molecule) • ITGAM (Integrin, alpha M) • ITGA4 (Integrin, alpha 4) • ITGAX (Integrin Subunit Alpha X) • ANPEP (Alanyl Aminopeptidase, Membrane) • CCR3 (C-C Motif Chemokine Receptor 3) • ITGA6 (Integrin, alpha 6) • ITGB1 (Integrin Subunit Beta 1) • SIGLEC8 (Sialic Acid Binding Ig Like Lectin 8)
    25d
    A Case of a Gastrointestinal Stromal Tumor of the Stomach with Lymph Node Metastasis (PubMed, Gan To Kagaku Ryoho)
    Tumor invades pancreatic tail, and lymph node metastasis was observed. She was discharged on the postoperative day 27 and alive without tumor recurrence at 6 months after surgery, not undergoing adjuvant chemotherapy.
    Journal • Stroma
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule)
    26d
    Evaluation and Management of Testicular Cancer After Late Relapse. (PubMed, Oncology (Williston Park))
    This patient likely had a contralateral late relapse of his original right NSGCT after 11 years of remission. The patient's original cancer was on the right side, with recurrence surrounding the aorta on the contralateral side, representing an atypical pattern of spread.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • AFP (Alpha-fetoprotein) • SALL4 (Spalt Like Transcription Factor 4)
    26d
    Computed tomography radiogenomics: A potential tool for prediction of molecular subtypes in gastric stromal tumor. (PubMed, World J Gastrointest Oncol)
    Our findings demonstrate that the combined modelCT sign + rad + clinic effectively distinguishes GISTs with KIT exon 11 mutation and KIT exon 11 codons 557-558 deletions. This combined model has the potential to be valuable in assessing the genotype of GISTs.
    Journal • Stroma
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • KIT exon 11 mutation
    26d
    A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov)
    P3, N=680, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2024 --> Jul 2024
    Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD19 (CD19 Molecule) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CSF1R (Colony stimulating factor 1 receptor)
    |
    CD19 expression
    |
    TruSight RNA Pan-Cancer Panel
    |
    dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)
    28d
    A Drug-drug Interaction Study of Avapritinib and Midazolam (clinicaltrials.gov)
    P1, N=10, Completed, Blueprint Medicines Corporation | Recruiting --> Completed | N=20 --> 10 | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Nov 2023 --> Mar 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Stroma • Metastases
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    Ayvakit (avapritinib)
    1m
    MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. (PubMed, J Clin Invest)
    No abstract available
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    1m
    Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial. (PubMed, EClinicalMedicine)
    Patients with clinical stage II/III TNBC were treated with 5 cycles of anlotinib (12 mg, d1-14, q3w) plus 6 cycles of taxanes (docetaxel 75 mg/m2 ,d1, q3w or nab-paclitaxel 125 mg/m2, d1 and d8, q3w) and lobaplatin (30 mg/m2, d1, q3w), followed by surgery. The addition of anlotinib to neoadjuvant chemotherapy showed manageable toxicity and encouraging antitumor activity for patients with clinical stage II/III TNBC. Chongqing Talents Project, Chongqing Key Project of Technology Innovation and Application Development and Chongqing Outstanding Youth Natural Science Foundation.
    P2 data • Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • AR (Androgen receptor) • FGFR (Fibroblast Growth Factor Receptor)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative
    |
    docetaxel • Focus V (anlotinib) • albumin-bound paclitaxel • lobaplatin (D19466)
    1m
    Salivary carcinoma showing thymus-like differentiation: clinicopathological analysis of 7 cases (PubMed, Zhonghua Kou Qiang Yi Xue Za Zhi)
    Salivary CASTLE is a rare tumor, it should be distinguished from lymphoepithelial carcinoma and squamous cell carcinoma. The patients often have better prognosis and CD5 protein expression has a valuable role in the differential diagnosis.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD5 (CD5 Molecule)
    1m
    ETV6::NTRK3 Fusion-Positive Wild-Type Gastrointestinal Stromal Tumor (GIST) with Abundant Lymphoid Infiltration (TILs and Tertiary Lymphoid Structures): A Report on a New Case with Therapeutic Implications and a Literature Review. (PubMed, Int J Mol Sci)
    The follow-up CT scan revealed peritoneal nodules suggestive of peritoneal dissemination, and Entrectinib (a TRK inhibitor) was administered...The present case may offer new insights into the potential introduction of TRK inhibitors as treatments for GISTs with NTRK fusions. Additionally, the presence of abundant lymphoid infiltration in the present case may prompt further research into immunotherapy as a possible additional therapeutic option.
    Clinical • Observational data • Retrospective data • Review • Journal • IO biomarker • Stroma
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • RB1 (RB Transcriptional Corepressor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • ETV6 (ETS Variant Transcription Factor 6) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • TFG (Trafficking From ER To Golgi Regulator) • NTRK (Neurotrophic receptor tyrosine kinase) • ANO1 (Anoctamin 1)
    |
    NTRK3 fusion • RB1 mutation • PDGFRA mutation • NTRK3 positive • NTRK fusion
    |
    Rozlytrek (entrectinib)
    1m
    Selected markers of ovarian cancer and their relation to targeted therapy (Review). (PubMed, Exp Ther Med)
    Drugs affecting cancer stem cells (CSCs) in OC, such as metformin and salinomycin, as well as inhibitors of CSCs markers aldehyde dehydrogenase 1 (with the drug ATRA) and the transcription factor Nanog homeobox (microRNA) are also discussed. A new approach to prevention and possible therapies under investigation such as development of vaccines containing a subpopulation of CD117(+) and CD44(+) stem cells with a promising option for use in women with OC was described.
    Review • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CDH1 (Cadherin 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • NANOG (Nanog Homeobox)
    |
    metformin • salinomycin (HSB-1216)
    1m
    Efficient generation of cloned cats with altered coat colour by editing of the KIT gene. (PubMed, Theriogenology)
    To our knowledge, this is the first report on coat colour modification of cats through gene editing. The findings could facilitate further understanding of the regulatory role of KIT on feline coat colour and provide a basis for the breeding of cats with commercially desired coat colour.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation
    1m
    A basaloid carcinoma with multilocular thymic cyst mimicking a mediastinal teratoma. (PubMed, J Cardiothorac Surg)
    This case report contributes to the growing understanding of thymic basaloid carcinoma, a rare and potentially aggressive thymic carcinoma subtype. It emphasizes the necessity for precise surgical techniques and enhanced diagnostic acumen among cardiothoracic surgeons and oncologists.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • TP63 (Tumor protein 63)
    1m
    Clinical, Epidemiological, Morphological, and Immunohistochemical Aspects of Nasopharyngeal Carcinoma-4-Year Retrospective Study in the Western Part of Romania. (PubMed, Diagnostics (Basel))
    The T cells were CD4- and CD8-positive, predominantly intratumoral, and the CD4:CD8 ratio was 1:1 for 75% of the undifferentiated subtype and 89% for differentiated non-keratinized squamous cell carcinoma. All subtypes of nasopharyngeal carcinoma presented with an inflammatory infiltrate with numerous plasma cells, eosinophils, and dendritic cells, presenting as antigen CD1a- and CD68-positive, as well as in CD117-positive mast cells.
    Retrospective data • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • TP63 (Tumor protein 63)
    |
    CD20 positive • CD8 positive • CD68 positive
    1m
    Aberrant METTL14 gene expression contributes to malignant transformation of benzene-exposed myeloid cells. (PubMed, Ecotoxicol Environ Saf)
    This upregulation of target gene expression activated signalling pathways such as mTOR-AKT, ultimately resulting in malignant proliferation of bone marrow cells. In conclusion, this study offers insights into potential early targets for benzene-induced haematologic malignant diseases and provides novel perspectives for more targeted preventive and therapeutic strategies.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • mTOR (Mechanistic target of rapamycin kinase) • METTL14 (Methyltransferase 14)
    |
    KIT expression • KIT overexpression
    1m
    Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma. (PubMed, Expert Opin Pharmacother)
    On the contrary, some patients with mucosal, acral or KIT-mutant melanoma may benefit from TKI-based therapies. Further studies focused on biomarker discovery and randomized trials are necessary to better understand the role of VEGFR1-3 as a therapeutic target in melanoma.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • FLT1 (Fms-related tyrosine kinase 1)
    |
    KIT mutation
    |
    Lenvima (lenvatinib) • AiTan (rivoceranib) • Inlyta (axitinib)
    1m
    A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma (clinicaltrials.gov)
    P=N/A, N=6, Active, not recruiting, Daiichi Sankyo Co., Ltd. | Phase classification: P1/2 --> P=N/A | Trial completion date: Mar 2024 --> Mar 2025
    Phase classification • Trial completion date • Metastases
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation
    |
    Turalio (pexidartinib)
    1m
    Molecular Analysis of Murine KitK641E Melanoma Progression. (PubMed, JID Innov)
    Finally, tumor escalation pathways proved consistent with immune evasion, with immune-related pathways becoming significantly downregulated. To our knowledge, it is previously unreported that these critical milestones needed for KIT-driven melanoma tumor formation have been studied at the molecular level using isogenically matched and phenotypically defined cells.
    Preclinical • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation
    1m
    Treatment Access for Gastrointestinal Stromal Tumor in Predominantly Low- and Middle-Income Countries. (PubMed, JAMA Netw Open)
    Gastrointestinal stromal tumor (GIST) is a rare cancer treated with the tyrosine kinase inhibitors imatinib mesylate or sunitinib malate. In this cohort study of patients with GIST who were predominantly from LMICs and received orally administered therapy through the GIPAP or MAS programs, outcomes were similar to those observed in high-resource countries. These findings underscore the feasibility and relevance of administering oral anticancer therapy to a molecularly defined population in LMICs, addressing a critical gap in cancer care.
    Journal • Stroma
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    imatinib • sunitinib
    1m
    Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness. (PubMed, Expert Rev Mol Med)
    Clinical management is based on bulk tumour removal and standard chemoradiation with the alkylating drug temozolomide, but the tumour invariably recurs leading to patient's death...Regorafenib, a sorafenib derivative, targets kinases associated with angiogenesis (VEGFR 1-3), as well as oncogenesis (c-KIT, RET, FGFR) and stromal kinases (FGFR, PDGFR-b). It was already approved for metastatic colorectal cancers and hepatocellular carcinomas. The aim of the present review is to focus on both the molecular and clinical knowledge collected in these first three years of regorafenib use in GBM.
    Preclinical • Review • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • FGFR (Fibroblast Growth Factor Receptor) • FLT1 (Fms-related tyrosine kinase 1)
    |
    IDH wild-type
    |
    sorafenib • temozolomide • Stivarga (regorafenib)
    2ms
    Terminal deoxynucleotidyl transferase expression in different subtypes of childhood B-cell acute lymphoblastic leukemia. (PubMed, Pathol Res Pract)
    Moreover, several aberrant markers, such as CD2, CD56, CD7, and CD117, were rarely expressed in the B-ALL samples, and if expressed, they were enriched in specific genetic subtypes. The results of this study indicate that immunophenotypic features are correlated with specific genetic subtypes of childhood B-ALL.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • NCAM1 (Neural cell adhesion molecule 1) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • MEF2D (Myocyte Enhancer Factor 2D)
    |
    KMT2A rearrangement • MLL rearrangement
    2ms
    Histomorphometric and Immunohistochemical Diagnosis of Renal Cell Carcinoma: Review Article. (PubMed, Mymensingh Med J)
    Here it has been found that chromophobe carcinoma is most commonly positive for CK7, EMA, CD117 and CAIX. In a patient coming with signs and symptoms of renal cell carcinoma can be confirmed with the help of histoimmunological markers and in that case one can plan for a proper planning of management.
    Review • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CA9 (Carbonic anhydrase 9)
    2ms
    Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Stroma
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT expression
    |
    sorafenib • imatinib • sunitinib
    2ms
    Sarcomatoid hepatocellular carcinoma: A case report and review of the literature. (PubMed, Medicine (Baltimore))
    SHC is a rare and aggressive liver cancer. So far, there is still a lack of effective therapeutic strategy, and the prognosis was dismal even though patients received radical surgical resection.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • CCND1 (Cyclin D1) • CD34 (CD34 molecule) • SOX10 (SRY-Box 10) • VIM (Vimentin) • KRT19 (Keratin 19) • ANO1 (Anoctamin 1)
    2ms
    Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis. (PubMed, Melanoma Res)
    Patients with heavier versus lower weights had lower mortality risk, which was more pronounced for BRAF-mutated patients. These relationships highlight the importance of demographic and pathologic relationships to aid in risk assessment and personalize treatment plans.
    Retrospective data • Journal
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    BRAF mutation • NRAS mutation • KIT mutation • NRAS wild-type
    2ms
    Imatinib TDM in GIST (clinicaltrials.gov)
    P2, N=28, Recruiting, Reema A. Patel | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment open • Trial primary completion date • Stroma
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA D842V • PDGFRA mutation
    |
    imatinib